Simplex Trading’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-1,407
Closed -$74.2K – 9427
2026
Q1
$66.9K Buy
+1,407
New +$74.2K ﹤0.01% 5538
2025
Q1
– Sell
-83,134
Closed -$3.52M – 8665
2024
Q4
$3.27M Buy
83,134
+16,254
+24% +$768K ﹤0.01% 1787
2024
Q3
$3.14M Buy
+66,880
New +$3.39M ﹤0.01% 1883
2023
Q4
– Sell
-34,794
Closed -$1.92M – 8921
2023
Q3
$1.58M Buy
34,794
+32,454
+1,387% +$1.68M ﹤0.01% 2284
2023
Q2
$131K Sell
2,340
-13,437
-85% -$762K ﹤0.01% 4760
2023
Q1
$713K Buy
15,777
+9,919
+169% +$482K ﹤0.01% 2913
2022
Q4
$238K Buy
5,858
+3,518
+150% +$187K ﹤0.01% 4016
2022
Q3
$152K Hold
2,340
– – ﹤0.01% 4968
2022
Q2
$142K Sell
2,340
-14,298
-86% -$841K ﹤0.01% 5071
2022
Q1
$1.04M Buy
16,638
+3,217
+24% +$202K ﹤0.01% 2868
2021
Q4
$1.02M Sell
13,421
-1,765
-12% -$154K ﹤0.01% 2828
2021
Q3
$2.38M Buy
15,186
+412
+3% +$51.7K ﹤0.01% 1943
2021
Q2
$2.39M Buy
14,774
+12,794
+646% +$1.56M ﹤0.01% 1938
2021
Q1
$241K Sell
1,980
-11,953
-86% -$1.8M ﹤0.01% 4458
2020
Q4
$2.13M Buy
+13,933
New +$1.65M ﹤0.01% 1718
2020
Q3
– Sell
-5,082
Closed -$451K – 7869
2020
Q2
$373K Buy
5,082
+4,991
+5,485% +$292K ﹤0.01% 3259
2020
Q1
$3K Buy
+91
New +$4.7K ﹤0.01% 7040
2018
Q2
– Sell
-20,015
Closed -$1.14M – 7427
2018
Q1
$914K Buy
20,015
+17,247
+623% +$712K 0.04% 428
2017
Q4
$64K Sell
2,768
-555
-17% -$10.5K ﹤0.01% 2196
2017
Q3
$59K Buy
+3,323
New +$60.3K ﹤0.01% 2149

Other funds holding CRSP

Simplex Trading's CRSP Position: Q2 2026 in Review

Simplex Trading sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 1,407 shares — an estimated $74.2K sold.

Simplex Trading first reported a position in CRSP in Q3 2017 and held it in 20 quarters. The position peaked at $3.27M in Q4 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Simplex Trading reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 1,407 CRISPR Therapeutics shares in Q2 2026, an estimated $74.2K.
  • Simplex Trading first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 20 quarters.
  • Simplex Trading's CRISPR Therapeutics position peaked at $3.27M in Q4 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.